SEO Friendly Free Article Directory

Submit your article for free.

Site Stats

10 users online
Total Categories: 131
Total Articles: 20562
Total Authors: 8019


Word Count: 259 || Page Views: 28 || Rating: Not yet rated || Print Preview ||

Rimonabant (Acomplia/Zimulti) Weight Loss Drug

Rimonabant (Acomplia), the new age weight loss drug is developed by world's third largest French pharmaceutical Sanofi-Aventis, to help ever growing number of obese population across the world. Rimonabant is sold under brand name of Acomplia in Europe and under the name as Zimulti in USA.

Accomplia (Remonabant) is a new weight loss drug manufactured by Sanofi french pharma company. Remonabant Accomplia helps for the treatment of obesity. Remonabant accomplia works by blocking CB1 receptors which ultimately makes person less hungry.

This Drug Accomplia Remonabant is also known as Miracle drug as it helps people to lose weight and acts as Anti-Munchie Drug.
Acomplia Remonabant may also help reduce the level of fats in the blood. Rimonabant Acomplia has been formerly manufactured for the obesity treatment. But this drug Acomplia Rimonabant helps smokers to quit smoking and to some extent Rimonabant Acomplia helps to stop alcoholism as well.

How Acomplia/Rimonabant/Zimulti Works? Acomplia (Rimonabant/Zimulti) diet pill works by blocking receptors of a substance called cannabinoid 1, which stimulates hunger and other cravings in the brain and is also present in fat tissue.
Acomplia's novel mode of action targets the same biological "switch" in the brain that makes people hungry when they smoke cannabis. The drug binds to and blocks a so-called cannabinoid receptor protein found on the surface of brain cells.

Obese patients treated for one year on the highest dose of 20 mg per day shed an average of 19 pounds and lost 3.5 inches of waistline, researchers showed, while 39 percent lost more than one-10th of their body weight.





About the Author

Acomplia is an anti- obesity oral prescription drug with Rimonabant as its chief constituent.

Author Profile: lazyurl

Rate This Article

Current Rating: Not yet rated


Comments

No comments posted.

Add Comment


Enter the code shown

Visual CAPTCHA